Royalty Pharma (RPRX) Stock
NASDAQ · RPRX
58.44
Fundamentals
Market cap
$26.01B
Price / Earnings ratio
41.2x
Price / Sales ratio
13.2x
Price / Book ratio
3.4x
Return on assets
0.0%
Ex-Dividend date
14 Aug 2026
Last payment date
N/A
Dividend amount
$0.24
Dividend yield
1.6%
Debt / Equity ratio
N/A
Latest news
About Royalty Pharma
Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry. Since our founding in 1996, we have been pioneers in the royalty market, collaborating with innovators from academic institutions and not-for-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies. We have assembled a portfolio of royalties which entitles us to payments based directly on the top-line sales of many of the industry’s leading therapies.
SectorHealthcare
IndustryBiotechnology
Employees100
CEOMr. Pablo Legorreta
IPO DateJun 16, 2020
HeadquartersNew York, NY
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Pablo Legorreta | Founder, Chairman of the Board & CEO | 1963 |
| Mr. Terrance P. Coyne | Executive VP & CFO | — |
| Mr. Christopher Hite | Chairman of Partnering & Investments | 1967 |
| Dr. Marshall Jonathan Urist M.D., Ph.D. | Head of Research & Investments | 1976 |
| Mr. Greg Butz | Executive Vice President of Partnering & Investments | — |
| Mr. Eric Cornelius Schneider | Senior VP & Chief Technology Officer | — |
| Dr. James Folmar Reddoch Ph.D. | Executive VP of Investments & Chief Scientific Officer | 1970 |
| Mr. George Grofik C.F.A., CPA | Senior VP and Head of Investor Relations & Communications | — |
| Mr. Arthur Richard McGivern J.D. | Executive VP of Investment & Chief Legal Officer | 1975 |
| Ms. Molly Sawaya | Executive VP & Head of Human Capital | — |
Fundamentals
Valuation
Market cap$26.01B
Price-to-sales ratio13.24
Price-to-book value3.43
Price-earnings ratio41.20
Return on Equity9.00%
Return on Sales0.48%
Return on Assets0.04%
PEG ratio1.36
Earnings Per Share
Earnings Per Share$1.88
Income Statement
Average volume3,171,632
EBITDA$1.17B
1 year high (52w)$64.38
1 year low (52w)$34.63
Dividend
Ex dividend date14 Aug 2026
Dividend amount$0.24
Dividend yield1.58%
Last payment dateN/A
Dividend yield (TTM)N/A
Next earnings reportN/A
Solvency
Debt-to-equity ratioN/A



